The FDA Is Ending Mass-Compounded Semaglutide and Tirzepatide: What Patients Should Do Now

If you have been paying $200 to $400 a month for compounded semaglutide or tirzepatide, the arrangement that made that price possible is ending. This is not a rumor or a proposed rule that might go nowhere — the underlying legal basis has already lapsed, and a second action now in progress will close most of what remains.

This article explains what changed, what is still permitted, what your costs realistically become, and how to handle the transition without undoing your results.

How Compounded GLP-1s Became Available in the First Place

Compounding pharmacies are generally prohibited from producing copies of commercially available FDA-approved drugs. There are two main exceptions. The first is a documented shortage: when a drug is on the FDA's shortage list, compounders may make it. The second is documented clinical customization for a specific patient — a different concentration, removal of an allergen, a combination the commercial product does not offer.

Between 2023 and 2025, semaglutide and tirzepatide were both in shortage. That opened the first exception wide, and an entire industry grew inside it: telehealth platforms, med-spa GLP-1 programs, and 503B outsourcing facilities producing compounded GLP-1s at a fraction of brand pricing.

That industry existed because of a supply failure. When the supply failure ended, so did its legal foundation.

What Has Actually Changed

The shortages resolved

Ozempic, Wegovy, Mounjaro, and Zepbound are all commercially available. With no shortage, the shortage exemption does not apply. This part is already done — it is not pending or proposed.

The 503B pathway is being closed

On April 30, 2026, the FDA proposed removing semaglutide and tirzepatide from the 503B outsourcing facility bulks list. 503B facilities are the ones that compound in large batches without patient-specific prescriptions — the supply backbone for most large telehealth GLP-1 programs.

The public comment period closed on June 29, 2026. Industry analysts broadly expect the removal to be finalized in the second half of 2026. When it is, large-scale compounded GLP-1 production in the United States effectively ends.

What survives: narrow 503A compounding

Patient-specific 503A compounding remains lawful, but the conditions are tighter than most patients have been told. All of the following must hold:

• The pharmacy uses semaglutide or tirzepatide base — not a salt form such as semaglutide sodium or semaglutide acetate. Salt forms are not permitted, and they were widely used during the shortage era.
• The pharmacy holds appropriate state licensure.
• There is a patient-specific prescription from a prescriber licensed in your state.
• The preparation is not essentially a copy of the commercial product, absent a documented clinical difference for you specifically.
• The preparation is not on the FDA's demonstrably-difficult-to-compound list.

That fourth condition is the one that quietly disqualifies most current arrangements. A flat monthly subscription for standard-dose compounded semaglutide, sold identically to thousands of patients, is difficult to characterize as individualized clinical customization.

A Safety Finding Worth Knowing About

Separately from the regulatory question: a 2026 study found that when compounded tirzepatide is mixed with vitamin B12 — a combination frequently marketed as reducing side effects or boosting energy — the two substances can chemically bond, forming a molecule that does not exist in the FDA-approved drug. Eli Lilly replicated the finding.

The clinical consequences are unknown. That is not reassurance; it is the actual problem. If you are on a compounded tirzepatide-B12 combination, this is worth raising with your prescriber directly.

What Your Costs Realistically Become

Patients moving off compounded product generally land in one of these places:

Path	Typical monthly cost	Notes
Brand GLP-1 with good insurance coverage	$25-$150	Best case. Requires coverage for the indication and usually prior authorization.
Brand GLP-1, manufacturer direct-pay	$350-$700	Manufacturer cash-pay programs have expanded considerably.
Orforglipron (Foundayo), oral	$50 for eligible Medicare Part D; otherwise varies	Approved April 2026. Lower efficacy (~12.4%) than top injectables.
Brand GLP-1, no coverage, no program	$900-$1,400	The scenario driving most people to compounded product originally.

One clarification, because it causes real confusion: semaglutide's patent expiry does not help American patients yet. Composition-of-matter patents expired in April 2026 in India, China, Canada, Brazil, and Turkey, and Health Canada approved a generic. Analyses suggest generic injectable semaglutide could eventually cost as little as $28 to $140 per person-year in those markets. In the United States, an FDA-approved generic or biosimilar is not expected until roughly 2033 to 2036. Headlines about $14 generics are describing other countries.

What to Do Now

1. Ask your provider which pathway they are compounding under. Not whether it is legal — which pathway. If the answer is vague, or references a shortage, that program is operating on a basis that has lapsed.
2. Confirm base versus salt form. If your pharmacy is using semaglutide sodium or another salt, that is not a permitted form. This is a direct, answerable question.
3. Do not stockpile. It is the common reflex and a poor idea — compounded product has limited stability, storage requirements are real, and you would be committing money to a supply chain that is being dismantled.
4. Get a coverage determination in writing. Coverage often turns on documentation quality. A letter of medical necessity with correct ICD-10 coding and documented comorbidities is frequently the difference between approval and denial.
5. Discuss dose strategy before you are forced into it. If cost is about to rise sharply, a planned maintenance dose is a better conversation to have deliberately than one you improvise after a supply interruption. Abrupt discontinuation tends to produce rapid weight regain.
6. Do not substitute gray-market product. The "research use only" market is not a cheaper version of the same thing. Independent testing has repeatedly found inaccurate dosing, contamination, and mislabeled compounds.

The Realistic Outlook

The era of inexpensive, widely available compounded GLP-1s in the United States is closing, and there is no obvious replacement for it before the 2030s. What partially fills the gap is oral GLP-1s — orforglipron in particular, which is cheaper to manufacture as a small molecule and reaches Medicare Part D patients at $50 a month — and expanded manufacturer cash-pay programs.

Neither fully substitutes for a $250 compounded vial. Patients who built a long-term plan around compounded pricing should be rebuilding it now, while there is still time to do it deliberately.